Global University Venturing

The TU Munich-linked venture capital firm has increased its third fund by more than $100m after launching it nearly a year ago.

The Stanford StartX-backed healthcare administration platform developer raised series C financing that took its overall funding to $160m.

The plant-based food producer increased its overall funding to almost $2bn in a round that brought the Stanford-linked company’s valuation to a reported $7bn.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

IP Group has returned for a series B round raised by Ieso Digital Health, having initially acquired stakes in the business through its purchase of Touchstone.

Sino Biopharmaceutical co-led the oncology treatment developer's latest round, in which it raised over $91m in funding.

IP Group returned for the Bristol spinout's series D that will go to product development and commercialisation.

Bringing together researchers from Italy and the US, Chroma Medicine has emerged out of stealth with series A financing led by Cormorant Asset Management.

The neuromodulation-focused Stanford spinout increased its overall funding to $145m in a round led by Ascension Ventures.

Kindred Ventures led the healthcare services provider's series E round, valuing it at $4.6bn.